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Thromboembolic Events During Chemotherapy for Germ
teii Cancer: A Cohort Study and Review of the Literatlire
By Mir l. Weijl, Marc F.J. Ruften, Aeilko H. Zwinderman, H. Jan Keizer, Marianne A. Nooy, Frits R. Rosendaal,
Frans J. Cleton, and Susanne Osanto
Purpose: To evaluate the risk of major thromboem-
bolic complications in male germ cell cancer patients
receiving cisplatin-based chemotherapy and to review
the literature on this subject.
Patients and Methods: One hundred seventy-nine
germ cell cancer patients treated between January 1979
and May 1997 in our Hospital were analyzed with respect
to risk factors for developing thromboembolic events,
such äs baseline tumor characteristics, prior tumor ther-
apy, administration of cytostatic agents, and the use of
antiemetic drugs. The patients were treated with a variety
of combination chemotherapy regimens, primarily cispla-
rin-containing combination regimens.
Results: Of the 179 patients, 15 patients (8.4%)
were identified who developed a total of 18 major
thromboembolic complications in the time period be-
tween the start of chemotherapy and 6 weeks öfter
administration of the last cytostatic drug in first-line
treatment. Of these 18 events, three (16.7%) were
arterial events, including two cerebral ischemic strokes,
and 15 (83.3%) were venous thromboembolic events,
including 11 pulmonary embolisms. One (5.6%) of the
18 events was fatal. Liver metastases (odds ratio, 4.9;
95% confidence interval, 1.1 to 20.8) and the adminis-
tration of high doses of corticosteroids (a 80 mg dexa-
methasone per cycle; odds ratio, 3.5; 95% confidence
interval, l .2 to 10.3) äs antiemetic therapy were iden-
tified äs risk factors for the development of major
thromboembolic complications.
Conclusion: Germ cell cancer patients who receive
chemotherapy, in particular those who have liver me-
tastases or receive high doses of corticosteroids, are at
considerable risk of developing thromboembolic
complications.
J C/ι'η Oncol 18:2169-2178. © 2000 by American
Society of Clinical Oncology.
THE INTRODUCTION OF cisplatin-based regimens forthe treatment of patients with disseminated germ cell
cancer has resulted in high remission rates and much
improved survival. As a larger number of germ cell cancer
patients are cured and become long-term survivors, in-
creased attention has been focused on treatment-induced
organ damage. The spectrum of chemotherapy-related com-
plications, such äs cisplatin-related damage to the kidney
and peripheral nerves and bleomycin-induced pulmonary
fibrosis, has been well documented. However, thromboem-
bolic complications, such äs pulmonary embolism, myocar-
dial infarction, and stroke, in relation to the chemotherapy
for germ cell cancer has primarily been described in case
reports,1"19 whereas only a few studies exist concerning the
incidence of thromboembolic toxicity in these patients.20"29
The etiology of thromboembolisms is thought to be multi-
causal.30 Disease and treatment-related factors, such äs
surgery, periods of immobilization, and the hypercoagulable
state of patients with (adeno)carcinoma, have often been
associated with venous thromboembolic events in cancer
patients.31"32 Several other mechanisms have been hypoth-
esized for the occurrence of venous and arterial thrombotic
complications in patients with disseminated germ cell can-
cer, including cisplatin-related hypomagnesemia, drug-in-
duced damage of the vascular endothelium, and elevation of
von Willebrand factor plasma levels.33 Recently, several
mutations have been described that increase the risk of
venous thrombosis in general, ie, in clotting factor V (factor
V 1691 G-to-A or factor V Leiden) and in prothrombin
(20210 G-to-A).34·35 Because these strong risk factors for
thrombosis (three- to eight-fold increased risk) are highly
prevalent in the general population (2% to 5% each),30 we
hypothesized that they contributed to the risk of thrombosis
in patients receiving chemotherapy.
Recently, a number of germ cell cancer patients treated with
chemotherapy in our department developed major thromboem-
bolic events, such äs cerebrovascular accidents and pulmonary
embolism. This prompted us to perform a retrospective study
to determine the incidence and fatality rate of thromboembolic
events and to assess which disease- and treatment-related
factors were associated with these life-threatening complica-
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tions in young men with a high chance of being cured of
malignancies. In addition, we reviewed the relevant literature,
with special emphasis on risk factors.
Table l. Risk Factors Analyzed
PATIENTS AND METHODS
Treatments
The medical records of 184 consecutive male patients with germ cell
cancer who underwent chemotherapy in the period between January
1979 until May 1997 in the Department of Clinical Oncology of the
Leiden University Medical Center were examined. Five patients were
excluded from analysis: four because their clinical records were
incomplete with regard to the administered drugs, and one because he
received only 2 days of chemotherapy and died 3 days later of
respiratory failure due to massive pulmonary metastases. Of the
remaining 179 patients, including 166 patients with primary testicular
tumors and 13 patients with primary extragonadal tumors, only the
thromboembolic events related to the first-line treatment were ana-
lyzed. The majority of patients received four to six cycles of intrave-
nously (IV) administered combination chemotherapy; cycles were
repeated every 21 days. Seventy-nine patients (44.1%) were treated
with the combination of bleomycin, etoposide, and cisplatin and 33
(18.4%) with cisplatin, vinblastine, and bleomycin. In these schedules,
cisplatin was administered during the first 2 or 5 days of each cycle, for
a total dose of 100 mg/m2 per cycle. Bleomycin was administered every
week (30 lU/wk), and vinblastine (0.15 mg/kg on days l and 2) and
etoposide during the first 3 to 5 days of each cycle, for a total etoposide
dose of 500 mg/m2 per cycle. The other patients were treated with a
variety of other combination chemotherapy schedules, primarily those
based on cisplatin, but 16 patients (8.9%) were treated with the
cisplatin analog carboplatin.
During the period from 1979 until the end of the 1980s, a wide ränge
of agents was used äs comedication against the cisplatin-induced
emesis, eg, benzamides, benzodiazepines, antihistamines, phenothia-
zines, and butyrophenones. After the introduction of corticosteroids
and serotonin-receptor antagonists äs superior antiemetic drugs, more
standardized antiemetic regimens were used, in which either serotonin-
receptor antagonists alone or in combination with corticosteroids were
administered before each cisplatin dosing, and the doses were then
tapered during the days thereafter.
Thromboembolic Events in Cases and Controls
Treatment-related thromboembolic events ("events") were defined äs
venous or arterial thrombosis or embolism occurring during the period
between the first day of chemotherapy and 6 weeks (42 days) after the
last administration of cytostatic drugs that belonged to the first-line
chemotherapy regimen. Superficial thrombophlebitis, often related to
the use of indwelling peripheral venous catheters, occurred frequently
but was not included in the analysis. Deep venous thrombosis (DVT)
presenting before the initiation of chemotherapy (n = 2), DVT
occurring more than 6 rnonths after the cessation of first-line chemo-
therapy (n = 3) or during second-line chemotherapy for a relapse of the
disease l year later (n = 1), and vena cava syndrome without evidence
of thrombosis in the caval or iliac vein (n = 4) were also not included
in the analysis. Patients who developed one or more thromboembolic
events were recorded äs cases; all other patients were recorded äs
controls. Eight of the controls, including two patients with DVT or
caval or iliac vein thrombosis before the Start of chemotherapy and six
other patients with a cardiovascular history, had already received
coumarin before the Start of chemotherapy.
• Age
• Body weight and length
• (Family) History of vascular disease
• Smoking habits
• Lung function parameters, ie, vital capacity and hemoglobin-corrected
diffusion capacity of lung for carbon monoxide
• Previous and concomitant surgical treatment or radiorherapy
• Histologie classification of primary tumor
• Side of primary testicular tumor (right or left)
• Extent of disease (sites of metastases)
• Prechemotherapy plasma tumor markers (erythrocyte Sedimentation rate,
lactate dehydrogenase, alpha-fetoprotein, beta-human chorionic
gonadotropin)
• Prechemotherapy hematocrit
• Administration and doses of:
• Cytostatic agents
• Corticosteroids äs part of antiemetic regimens
• Serotonin-receptor antagonists äs antiemetic therapy
• Hematopoietic growth factors (granulocyte colony-stimulating factor)
• Anticoagulant drugs (nonsteroidal anti-inflammatory drugs, coumarin,
or heparin)
• Use of permanent intravascular access devices
• Use of intravenous contrast agents
• Prolonged immobilization during chemotherapy
Risk Factors
Risk factors for developing thromboembolic events, äs mentioned in
the literature,28"33·36 were recorded (Table 1). Family history was
considered to be positive if two or more first- or second-degree family
members had a history of vascular disease. Patients who smoked one or
more cigarettes per day in the 12-month period before the initiation of
chemotherapy were defined äs smokers. The results of pretreatment
pulmonary function tests, available from patients treated with bleomy-
cin, were only included in the analysis if the tests had been performed
before the first administration of bleomycin.
The histologic classification of the major component of the primary
tumor according to the World Health Organization was used for the
diagnosis of the tumor,37 combining embryonal carcinoma and tumors
containing both embryonal carcinoma and teratoma into one group
hereafter referred to äs embryonal carcinoma. Other risk factors that
were analyzed included IV contrast agents,38 immobilization, and
surgery. IV contrast agents administered for radiologic investigations in
the 7 days preceding the thromboembolic event were scored; immobi-
lization and surgery were scored if present within a 30-day period
before the occurrence of thromboembolic events. The time period
during which the complete first-line treatment was administered,
including surgery after first-line chemotherapy (often retroperitoneal
lymph node dissection for residual tumor masses) and consolidation
chemotherapy, was included in our analysis.
Furthermore, for the cases, the creatinine clearance and serum
magnesium concentration, parameters of cisplatin-induced renal toxic-
ity (renal glomerular and tubular dysfunction, respectively) were
recorded at the time of the first thromboembolic event, reflecting
chemotherapy- and, in particular, cisplatin-induced toxicity. In addi-
tion, DNA isolated from WBCs of the 12 cases who are still alive was
analyzed for gene mutations in factor V Leiden and prothrombin (factor
II; 20210, G-to-A replacement), äs previously described.3435
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Table 2. Characteristics of fhe Individual Cases and Thromboembolic Events in Relation to (Chemo)Therapy
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Abbreviations: CT, chemotherapy; Surgery, lymph node dissection or orchidectomy; PE, pulmonary embolism; (D)VT, (deep) venous thrombosis; AT, arterial
thrombosis; v, vein; w, veins; a, artery; aa, arteries; embr ca, embryonal carcinoma; chorio ca, choriocarcinoma; abd In, abdominal lymph nodes; med In,
mediastinal lymph nodes; pulm, pulmonary; cerv In, cervical lymph nodes; PVB, cisplatin-vinblasHne-bleomycin; DOX, doxorubicin; BEP, cisplatin-etoposide-
bleomycin.
Statistical Analysis
We compared patients who experienced one or more thromboem-
bolic events during their chemotherapy course (cases) with patients
who did not experience such events (controls). The number of
chemotherapy cycles did not differ significantly between cases and
controls. Because all controls were observed for beyond the latest
occurring events, we decided to analyze these data äs a case-control
study. First, we compared the baseline and treatment-related Charac-
teristics between cases and controls using the χ2, Student's t-, or
Mann-Whitney tests, äs appropriate. To investigate possible risk
factors, we calculated odds ratios äs an estimate of the relative risk. The
odds ratios show how much higher the risk of disease, eg, thrombosis,
is in the presence of a risk factor than in its absence; an odds ratio of
l indicates the absence of an association. Second, we used multivari-
able logistic regression analysis to estimate the contributions of several
factors to the risk of thromboembolic events. Included in this multiva-
riable model were all variables that had either a P value of .05 or lower
in univariate analysis or an univariate odds ratio of 2.0 or higher.
RESULTS
Thromboembolic Events and Cases
Analysis of the first-line chemotherapy treatment period
of the 179 patients treated in our hospital revealed a total
of 18 major thromboembolic events. Fifteen (8.4%) of
the 179 patients developed major thromboembolic
events; 12 patients developed one and three patients
developed two thromboembolic events during chemo-
therapy (Table 2). Three of the 18 events were caused by
arterial thrombosis, namely, one patient (Table 2, patient
no. 8) with thrombosis of both abdominal and leg arteries
and two patients (Table 2, patients no. 10 and 15) with
cerebrovascular accidents. In total, 15 venous thrombo-
embolic events occurred in 13 patients (Table 2); these 13
cases developed DVT of the lower extremities (n = 2),
abdominal venous thrombosis (n = 2), or pulmonary
embolism (n = 11) and were treated with heparin and
oral anticoagulant drugs. In the nine patients with pul-
monary embolisms, the diagnosis was made with perfu-
sion or ventilation-perfusion scans.
The thromboembolic events occurred between 4 and 106
days after the Start of chemotherapy (mean interval for the
first event, 50 ± 33 days; median, 52 days). Only two events
occurred within l day after the administration of cisplatin
(median, 7 days after cisplatin administration), and two
other events occurred within l day after bleomycin admin-
istration (median, 3 days after bleomycin administration).
Fourteen cases underwent prior orchidectomy; in one
case (patient no. 5), the intra-abdominally located patho-
logic testis was removed after chemotherapy. In contrast to
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the more recently occumng thromboembolic events, five of
the events occumng in the period between 1981 and 1987
occurred within 10 to 22 days after surgery (Table 2). In all
five cases with abdominal or lower-extremity thromboem-
bolic events, extensive abdominal metastases were found
before the Start of chemotherapy. In these five cases, three
thromboembolic events occurred during the third and fourth
chemotherapy cycle, after marked tumor regression had
already occurred.
Of the 18 thromboembolic events that occurred, one
(5.6%) was fatal; this case (patient no. 15) died äs a
consequence of the cerebrovascular event. In the control
group, three (1.8%) of the 164 patients died, two because of
respiratory failure after bleomycin-induced pulmonary fi-
brosis and one because of heart failure more than 45 days
after the cessation of chemotherapy. Thus four (2.2%) of the
179 patients died äs a result of complications during
therapy. None of the cases had received IV contrast agents
nor been immobilized in the 7 days preceding the thrombo-
embolic event. Cases did not develop other excessive
chemotherapy-related toxicity, äs evidenced by the fact that
the mean creatinine clearance at the time of the first
thromboembolic event was 111 ±32 mL/min (ränge, 61 to
164 mL/min) and the mean serum magnesium concentration
was 0.73 ± 0.06 mmol/L (ränge, 0.64 to 0.85 mmol/L).
Furthermore, no gene mutations of factor V Leiden or
prothrombin were found in more recently analyzed leuko-
cyte DNA of 12 cases who were still alive, making it
unlikely that these two common risk factors for venous
thrombosis contributed to these events.
Patients' Baseline Characteristics and Administered
Chemotherapy
The baseline characteristics of cases and controls are
listed in Table 3. Cases and controls did not differ with
respect to age, body weight, and patient or family history of
vascular disease, nor with respect to hematocrit value or
lung function äs measured by vital capacity and carbon
monoxide diffusion capacity (age and patient's history of
vascular disease only are listed in Table 3). Also the
erythrocyte Sedimentation rate and the median levels of
lactate dehydrogenase and the serum tumor markers alpha-
fetoprotein and beta-human chorionic gonadotropin before
the Start of chemotherapy did not differ between cases and
controls. The percentage of patients who smoked and
patients who underwent a retroperitoneal lymph node dis-
section was higher in the control group, compared with the
cases (not statistically significant; Table 3). Cases and
controls did not differ with respect to the side on which the
primary testicular tumor had occurred (Table 3).
Eleven (73.3%) of the 15 cases had embryonal carci-
noma, and three cases (20.0%) had seminoma. In contrast,
80 (48.8%) of the controls had embryonal carcinoma and 71
(43.4%) had seminoma. Patients with liver metastases had
an increased risk for developing thromboembolic events
(odds ratio, 4.9; 95% confidence interval, 1.1 to 20.8).
Interestingly, patients who only had elevated tumor markers
and who did not have measurable disease had a slightly
increased risk for development of thromboembolic events
(odds ratio, 4.9; 95% confidence interval, 0.9 to 27.7).
All cases had been treated with both cisplatin and bleomy-
cin, in contrast to the controls, who, in some cases, received
carboplatin instead of cisplatin and who were not always
treated with bleomycin (data not shown). However, except for
carboplatin, the mean total administered dose of cytostatic
drugs was not different between cases and controls (Table 3).
The controls even received a much higher mean cumulative
dose of individual cytostatic drugs during the total treatment
period (4.9 ±2.1 cycles) than the mean cumulative dose of
cytostatic drugs received in the period until the occurrence of
the first thromboembolic event by the cases (2.7 ±1.3 cycles).
The total dose of administered cytostatic agents until the first
thromboembolic event was 521 ± 202 mg, 200 ± 103 mg,
1,639 ± 793 mg, and 56 ± 18 mg for cisplatin, bleomycin,
etoposide, and vinblastine, respectively.
Concomitant Surgery and Supportive Care—Related Risk
Factors
About half of the cases and controls received dexameth-
asone äs antiemetic therapy, whereas a higher percentage of
cases than controls received serotonin receptor antagonists
äs antiemetic therapy (Table 4). Cases received a signifi-
cantly higher mean dose of dexamethasone per cycle until
the first thromboembolic event, compared with the mean
dose of dexamethasone per cycle administered to controls
during the entire treatment period (Table 4; Student's t lest
P = .004). High doses of corticosteroids, narnely 80 mg or
more of dexamethasone per cycle, were identified äs a risk
factor for the occurrence of thromboembolic complications
(Table 4; odds ratio, 3.5; 95% confidence interval, 1.2 to 10.3).
None of the cases received hematopoietic growth factors
or permanent intravascular access devices before the occur-
rence of the thromboembolic event. One of the cases and
eight of the controls received nonsteroidal anti-inflamma-
tory drugs, and eight of the controls received coumarin äs an
anticoagulant before the Start of chemotherapy and during
chemotherapy (see Patients and Methods).
Multivariable Logistic Regression Analysis
Multivariable logistic regression analysis identified both
liver metastases and high doses of corticosteroids (3: 80 mg
Ί
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Table 3. Baseline and Chemotherapy Characteristlcs of Cases and Controls
Age, years, mean ± SD
Histoty of vascular disease
Smoking habits
Prior orchidectomy












Right-sided primary testicular tumor
Extragonadal tumor
Site of metastases





Visceral organs, excluding liver
No. of chemotherapy cycles, mean ± SD
Total dose of administered cytostatic




































































































































Abbreviations: ESR, erythrocyte Sedimentation rate; LDH, serum levels of lactate dehydrogenase; a-FP, serum levels of alpha-fetoprotein; /3-HCG, serum levels
of beta-human chorionic gonadotropin.
"Significance of t test (P) for metric parameters.
tPatients who did not receive the drug were excluded.
dexamethasone per cycle), but not embryonal carcinoma or
the presence only of elevated tumor markers, äs independent
risk factors for the development of thromboembolic com-
plications during treatment (Table 5).
Review of the Literature
We reviewed the literature with respect to thromboem-
bolic events occurring in germ cell cancer patients. Only
thromboembolic events occurring in the time period after
the Start of chemotherapy until 42 days after the completion
of chemotherapy were included in this review. Raynaud's
phenomenon, unproven thromboembolic events such äs
"ehest pain" without ECG changes, congestive heart failure,
and "minor" events such äs superficial thrombophlebitis
were not taken into account. However, in contrast to our
own 15 cases reported (Table 2), we did include in this
review a few patients who developed thromboembolic
complications during second-line chemotherapy. We thus
identified 28 reports dealing with this subject. In these 28
reports, 48 germ cell cancer cases who developed a total of
56 proven major thromboembolic events were described
(Table o).1'28
Of the 56 thromboembolic events reported in the litera-
ture, 35 events (61.4%) occurred äs a result of arterial
disease; namely, 18 myocardial infarctions, 10 cerebrovas-
cular events, and seven peripheral arterial occlusions. In our
patients, only three (17%) of the 18 events were of arterial
origin. The other 21 events reported in the literature
consisted of 15 cases of D VT of the extremities or abdomen
and six pulmonary embolisms.
J
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Table 4. Concomitant Surgery and Supportive Care-Related Risk Factors of Cases and Controls





Concomitant surgery during chemotherapy
Dexamethasone
Dose of dexamethasone/cycle
£ 20 mg dexamethasone/cycle
> 40 mg dexamethasone/cycle
s 60 mg dexamethasone/cycle
s 80 mg dexamethasone/cycle
Total dexamethasone dose, mg (mean ± SD)||




















































































*Odds ratio and 95% confidence interval for nominal parameters.
tComparing values of cases before thromboembollc event and of controls during the entire treatment.
tSignificance of f test (P) for metric parameters.
§Comparing doses administered to cases and controls during the entire treatment.
IJPatients who did not receive the drug were excluded.
Patients' ages, primary tumor histologies, and sites of
metastases were not always reported in the literature. At
least 11 (34.4%) of the 32 cases for whom age was reported
were more than 40 years of age, and in 10 of the 11 cases
the thromboembolic events reported were of arterial origin.
In our series, only two (13%) of the 15 cases were more than
40 years of age. Eleven of the 53 thromboembolic events
reported in the literature were fatal; of these 11 fatal events,
six concerned venous thromboembolic events and the other
five were arterial thromboembolic events. In seven studies
dealing with various chemotherapy-related toxicities in
large groups of germ cell cancer patients, the incidences of
cardiovascular complications varied between 0.6% and
15.3%.20-25·27
D1SCUSS1ON
In this study, a high incidence of major thromboembolic
events was found in 15 (8.4%) of the 179 germ cell cancer
patients undergoing chemotherapy in our department. Sev-
enteen percent of the events were arterial, and one of the 18
events that occurred was fatal. Three cases developed two
major thromboembolic events: two developed two venous
Table 5. Multivariable Logistic Regression Analysis
Embryonal carcinoma
Elevated tumor markers only
Mediastinal lymph nodes
Liver metastases













events, whereas one developed a venous and an arterial
event. Liver metastases and the administration of high doses
of dexamethasone äs antiemetic therapy were identified äs
risk factors for the development of thromboembolic com-
plications. Interestingly, cases did not have excessive (oth-
er) chemotherapy-related toxicity at the time that the throm-
boembolic event occurred. No gene mutations of factor V
Leiden or prothrombin were found in the cases. In the early
1980s, there seemed to be a temporal association between
the occurrence of thromboembolic events and recent surgi-
cal treatment, whereas thromboembolic events that occurred
since 1991 were often related to the use of high doses of the
corticosteroid dexamethasone äs an antiemetic.
In addition to the 15 patients who had thromboembolic
events during chemotherapy, six additional patients had
DVT before the Start of chemotherapy, more than 6 months
after the cessation of chemotherapy, or during second-line
chemotherapy, resulting in an even higher incidence of
11.7% of the 179 included germ cell cancer patients treated
in our hospital in the time period studied. Bredael et al39
also found a high incidence of pulmonary embolism äs the
cause of death in 14 (9%) of the 144 autopsied germ cell
tumor patients, suggesting that humoral factors of the tumor
affect the hemostatic System. Most germ cell cancer cases
reported in the literature who developed thromboembolic
complications had embryonal carcinoma. In accordance
with Stockler et al,40 thromboembolic events occurred more
often in patients with this histologic tumor type, ie, embry-
onal cell carcinoma or embryonal cell carcinoma plus
teratoma, than in patients with seminoma. The Undings that
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Schmidt'7 45 choriocarcinoma abd In, pulm, liver
Lepidini18 40 choriocarcinoma pulm
Shlebak19 32 "germ-cell tumor" "stage IE"
37 seminoma "stage II"
Hassan28 NR NR















31 patients with inferior
vena cava obstruction; 2
developed DVT during
chemotherapy; l of
these 2 patients died of
PE
NR NR NR DVT
NOTE. Quoted text indicates citation from the article.
Abbreviations: NR, not reported in the article; embr ca, embryonal cell carcinoma; abd In, abdominal lymph nodes; abd-res, residual abdominal disease after
retroperitoneal lymph node dissection; med In, mediastinum; pulm, lungs; cerv In, cervical lymph nodes; thr, thrombosis; a, artery; MI, myocardial infarction; CVA,
cerebral vascular accident; PE, pulmonary embolism; DVT, deep venous thrombosis; v, vene; PVB, cisplatin, vinblastine, and bleomycin; vab-ό, cyclophosphamide,
vinblastine, bleomycin, dactinomycin, and cisplatin; EP, etoposide and cisplatin; DOX, doxorubicin; BEP, bleomycin, etoposide, and cisplatin; ACTD, actionomycin
D; MTX, methotrexate; IFX, ifosfamide; VIP, vinblastine, ifosfamide, and cisplatin; PV, cisplatin and vinblastine; POMBACE, cisplatin, vincristine, methotrexate,
bleomycin, actinomycin D, cyclophosphamide, and etoposide; ACE, actinomycin D, cyclophosphamide, and etoposide; GCSF, granulocyte colony-stimulating
factor; ARDS, adult respiratory distress syndrome; ß-HCG, serum levels of beta-human chorionic gonadotropin.
'Possible pathogenetic factors were suggested by the authors. Numbers indicate the number of events/number of patients in study.
several human teratocarcinoma cell lines release plasma
membrane vesicles with procoagulant activity underscores
the theory that this tumor type may be associated with the
development of thromboembolic events.41
Other factors could explain why liver metastases are a
risk factor for thromboembolic events in germ cell cancer
patients. Although our Undings are based on a small number
of patients with liver metastases—namely, three cases and
eight controls—the association between liver metastases
and thromboembolic events has also been found in various
other malignancies,42·43 possibly because of the impaired
clearance of activated coagulation factors and the decreased
synthesis of anticoagulants in the liver.32·43 Massive abdom-
inal metastases (retroperitoneal lymph nodes and liver
metastases) äs a mechanical cause of venous thrombosis of
abdominal and femoral vessels7'22'28 seems unlikely, äs in
most of our patients, their large tumor masses that were
present before the start of chemotherapy had already re-
gressed by the time of the thromboembolic event.
One important finding of our study is that the adminis-
tration of high doses of corticosteroids (s 80 mg dexameth-
asone per cycle) is an independent risk factors for the
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development of thromboembolic events in germ cell cancer
patients undergoing chemotherapy. This is in agreement
with several reports about the hypercoagulable state of
patients with Cushing's syndrome44 and the occurrence of
thromboembolic events in patients receiving high doses of
corticosteroids or adrenocorticotropic hormone for various
nonmalignant indications.45"47 Also, the concomitant ad-
ministration of corticosteroids äs antiemetic therapy during
chemotherapy in patients with germ cell cancer12 and
ovarian carcinoma48 was suspected äs the direct cause of
thromboembolic events. Liver metastases and the adminis-
tration of high doses of corticosteroids led to a considerable
increased risk of venous thrombosis (three- to eight-fold
increased risk). However, the numbers of cases and controls
were small, and the contribution of these two factors to the
occurrence of thromboembolisms should be confirmed in an
independent study.
Various mechanisms contribute to the hypercoagulability
induced by corticosteroids. For instance, corticosteroids may
inhibit blood fibrinolytic activity49 and decrease platelet count
and levels of the clotting factor VÜI/von Willebrand factor
complex.50 In addition, corticosteroids are known to decrease
cerebral blood flow by their direct vasoconstrictive effect on
cerebral blood vessels, increase blood pressure, and decrease
the clearance rate of activated clotting factors by reticulocndo-
thelial blockade.51'52 Interestingly, in several studies of throm-
botic events occurring during chemotherapy for patients with
breast carcinoma53·54 and hematologic malignancies,55 patients
often received corticosteroids äs part of their antitumor che-
motherapy regimens.
Cardiovascular risk factors, such äs smoking and pre-
existing arterial disease, are frequently mentioned äs risk
factors for the development of thromboembolic events in
germ cell cancer patients.9·10·24·27 The older ages and more
frequently reported arterial thromboembolic complications
in the patients reported in the literature seem to agree with
this. The high number of arterial thromboembolic events
reported in the literature may result from selection bias
toward reporting arterial but not venous complications in
case reports.
The findings of our study indicate that germ cell cancer
patients who undergo chemotherapy are at considerable risk
of developing major thromboembolic complications. The
identification of high doses of corticosteroids, equivalent to
or greater than 80 mg dexamethasone per cycle, used äs
antiemetic therapy in highly emetogenic cisplatin-based
chemotherapy regimens, äs a risk factor for the development
of such thromboembolic events suggests that the use of high
doses of corticosteroids äs antiemetic therapy should be
avoided. On the basis of our findings, the prophylactic
administration of heparin may be considered in germ cell
cancer patients with liver metastases and in patients requir-
ing high doses of corticosteroids äs antiemetic therapy
during chemotherapy. However, further studies should in-
vestigate the need for such treatment äs well äs evaluate its
benefits. For instance, prophylactic administration of low-
molecular-weight heparin has been demonstrated to be
cost-effective in various other clinical settings56 and could
be considered in this patient population. Finally, because
germ cell cancer cells may produce factors that cause a
hypercoagulable state, we will investigate prospectively
whether prothrombotic abnormalities are indeed present in
patients with this type of cancer at the time of surgery or
during chemotherapy for metastatic disease.
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